Loading...
•
Dec 31, 2021
Black Diamond Therapeutics Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $25.9 million for Q4 2021, compared to a net loss of $22.6 million for the same period in 2020. The company's cash, cash equivalents, and investments totaled $209.8 million as of December 31, 2021, which is expected to fund operations into 2024.
Initiated Phase 1 study of BDTX-1535 for GBM and NSCLC after IND allowance by the FDA.
Presented preclinical data at AACR-NCI-EORTC (ANE) International Conference for MasterKey programs BDTX-1535, CNS-BRAF (BDTX-4933), and FGFR.
Appointed Elizabeth Montgomery as Chief People Officer.
Ended 2021 with $209.8 million in cash, cash equivalents, and investments, expected to be sufficient to fund operations into 2024.
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
Black Diamond believes that its cash, cash equivalents and investments of approximately $209.8 million is sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2024.